about
Comparison of parameters from Heidelberg Retina Tomographs 2 and 3.The correlation between retinal blood flow velocity measured by the retinal function imager and various physiological parameters.Retinal blood flow velocity in metabolic syndrome.High-resolution wide-field imaging of perfused capillaries without the use of contrast agentOptical coherence tomography machine learning classifiers for glaucoma detection: a preliminary study.Glaucoma detection with the Heidelberg retina tomograph 3.Glaucoma detection with matrix and standard achromatic perimetry.Segmental reproducibility of retinal blood flow velocity measurements using retinal function imager.Functional imaging using the retinal function imager: direct imaging of blood velocity, achieving fluorescein angiography-like images without any contrast agent, qualitative oximetry, and functional metabolic signals.Incision and Curettage Versus Steroid Injection for the Treatment of Chalazia: A Meta-Analysis.Reduced retinal blood flow velocity in diabetic retinopathy.Quantifying retinal nerve fiber layer loss in glaucoma using a model of unilateral hypertensive pseudoexfoliation syndrome.Compliance with eye care in glaucoma patients with comorbid depression.Inverse correlation between coronary and retinal blood flows in patients with normal coronary arteries and slow coronary blood flow.Evaluation of Critical Flicker-Fusion Frequency Measurement Methods for the Investigation of Visual Temporal Resolution.Inter-device variability of the Stratus optical coherence tomography.Hypotonous malignant glaucoma: aqueous misdirection with low intraocular pressure.Central serous chorioretinopathy shows reduced retinal flow circulation in retinal function imaging (RFI).Acute angle closure glaucoma precipitated by olanzapine.Predicting cataract surgery time based on preoperative risk assessment.Corneal Staining and Hot Black Tea Compresses.TOPICAL APRACLONIDINE REDUCES PAIN AFTER INTRAVITREAL INJECTIONS: A Double-Blind Randomized Controlled Trial.Retinal blood flow velocity in patients with age-related macular degeneration.
P50
Q34008140-BCD657BB-49B7-44B6-B39B-32D52B785D09Q34590431-D0051D98-E5A6-41FC-B828-844193C629A0Q34655880-E55278DF-F1BB-4449-ACAD-C6ABB6F16BE4Q35182552-CF2179BA-A895-446B-B1BA-4DAFEFB90514Q35928680-A0A5F573-BE42-4EB5-9326-8A4045B519B3Q35935234-4FD0267F-E716-4F62-A80B-38F6C88BE849Q35956347-8B6186C1-6F9D-41C9-A5EE-EBE18594D74AQ37397142-1CFF8A4F-578B-4ABC-966C-A5AECE17FA9CQ37599631-FB28D404-F262-4855-8AA5-13E210EF1796Q38512758-C7A63771-E4C5-4665-8F30-F7CAE3160F48Q43198302-251FAE6C-4AEA-4D09-934E-6AEEE5569F9BQ43262101-AAB3B04D-1032-47F5-BBBA-E13528D1AEBCQ44752649-6C3359EA-4F93-4D5C-86B5-FFE34FFEADD9Q44948978-AD2714BE-2361-4AF0-8C24-0A3B276BC38EQ45551867-D4F44F2D-93C8-4E3B-8151-78016ACF8161Q46331671-B16B805B-06F4-495A-8BA3-FD0A24B8E3FAQ46628120-C1A3A873-37F6-4031-BBE8-5C63E1730E36Q46636881-A2D1C04A-9B21-4A69-B8C0-4C720123FC8CQ48132988-DF5DAEAE-A84B-4B70-95DE-5F4FAB9816A7Q50778988-2A85B80A-A33A-40D0-8049-DA82DE92106EQ52680955-1DCD5634-31AA-4B78-9B0A-80B58615C8BEQ53552996-A0A16875-DCDC-4659-8283-8E81AF682137Q54714141-81205FEC-D2EC-46DE-AA51-A01F6D0C0E38
P50
name
Zvia Burgansky-Eliash
@en
Zvia Burgansky-Eliash
@nl
type
label
Zvia Burgansky-Eliash
@en
Zvia Burgansky-Eliash
@nl
prefLabel
Zvia Burgansky-Eliash
@en
Zvia Burgansky-Eliash
@nl